City Therapeutics
Tracy Zimmermann currently holds the position of Chief Scientific Officer at City Therapeutics, a role assumed in June 2024. Prior to this, Tracy served as Chief Development Officer and Vice President of Preclinical Research and Translational Biology at Generation Bio from October 2018 to December 2023. Tracy's extensive experience in research and development also includes senior roles at Alnylam Pharmaceuticals, where Tracy was Senior Director, Director, and Associate Director of Research between January 2010 and September 2018. Earlier in the career, Tracy worked as a Senior Scientist at Variagenics Inc. from June 2001 to June 2003. Tracy holds a Ph.D. in Chemistry from the University of Colorado Boulder and completed a postdoctoral fellowship in Dr. Pamela Silver's Lab at Harvard Medical School.
This person is not in any teams
This person is not in any offices
City Therapeutics
Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.